157. Switch to single-tablet bictegravir-lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial.
作者: Chloe Orkin.;Peter J Ruane.;Malcolm Hedgcock.;Cyril Gaultier.;Marcelo H Losso.;Benoit Trottier.;Thomas Lutz.;Mark O'Reilly.;Mark Bloch.;Jihad Slim.;Moti Ramgopal.;Simiso Sokhela.;Karam Mounzer.;Hung-Chin Tsai.;Jorge Santana Bagur.;Xu Zhang.;Keith Aizen.;Kwanza Price.;Nicolas Margot.;Jairo M Montezuma-Rusca.;Peter Sklar.;Martin Rhee.;Pedro Cahn.; .
来源: Lancet. 2026年407卷10535期1249-1258页
Single-tablet regimens (STRs) revolutionised HIV-1 treatment, improving adherence and clinical outcomes; however, many people cannot take these due to resistance, contraindications, or drug-drug interactions, instead relying on complex multi-tablet regimens. Novel STRs are therefore needed. We aimed to evaluate the efficacy and safety of a novel STR, bictegravir-lenacapavir, in people with HIV-1.
|